AVEO Pharmaceuticals — Investor Presentation (January 2016)
35 slides from AVEO Pharmaceuticals's investor presentation, Jan 5, 2016
Slide 1: January 2016 Corporate Overview
January 2016 Corporate Overview Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are
Slide 3: AVEO Oncology Highlights
AVEO Oncology Highlights Lead Asset: Tivozanib Core focus: retain North American tivozanib rights >$1Bn U.S. RCC market Partner Ex-N.A. (EUSA, Pharmstandard) and for ocular (Ophthotech) in 2014/15 Phase 3 TIVO-1 study demonstrated improved PFS in advanced RCC Study may support registration in Europe
Slide 4: Leveraging Biomarkers and Partnerships to Advance a Robust Pipeline
AVEO is Leveraging Biomarkers and Partnerships in Seeking to Advance a Robust Pipeline of Assets Program Pathway Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Partner Tivozanib VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 ERBB3 MAb AV-380 GDF15 MAb Most Advanced Stage Cachexia NRG-1 Biomarker S
Slide 5: Partnerships Provide Significant Downstream Value Potential
Partnerships Provide Significant Downstream Value Potential, Support for Tivozanib U.S. Strategy Tivozanib EU, Other December 2015 Tivozanib Ocular November 2014 Tivozanib Russia, Ukraine, CIS August 2015 AV-380 August 2015 Ficlatuzumab April 2014 >$850M in potential partnership payments plus meanin
Slide 6: Tivozanib
Tivozanib A potent, selective, long half-life inhibitor of vascular endothelial growth factor (VEGF) 1, 2 and 3 receptors
Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor
Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:
Slide 8: TIVO-1: Proven Activity in 1st Line RCC
Phase 3 TIVO-1: Proven Activity in 1st line RCC 517 patient, global, randomized Phase 3 in first line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; FDA requested additional study Demonstrated differentiated safety profile Months Probabi
Slide 9: Favorable Tolerability vs. Approved TKIs in RCC
Favorable Tolerability vs. Approved TKIs in RCC Incidence (%) Incidence (%) Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Dose Reductions Dose Interruptions Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 1. AVEO Data on file:2. INLYTA prescribing information
Slide 10: Top Three Toxicities Relevant to Patients with Advanced RCC
Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and
Slide 11: Comparable OS Despite Limited Subsequent Therapy
Comparable OS Despite Limited Subsequent Therapy
Slide 12: Tivozanib North American Registration Strategy in RCC
Tivozanib North American Registration Strategy in RCC
Slide 13: Potential Phase 3 Study Design in Recurrent/Metastatic RCC
Potential Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~314 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and tolerability for ITT & Pre-Spe
Slide 14: Significant Activity in TKI Refractory RCC
Significant Activity in TKI Refractory RCC Study AXIS Phase 3, axitinib vs sorafenib (1:1)1 TIVO-1 Phase 3, subset crossing over to tivozanib following sorafenib progression3 Dovitinib study Phase 3, dovitinib vs sorafenib (1:1)2 Setting 2nd line RCC 2nd line RCC 3rd line RCC Study Size n=361 (axiti
Slide 15: Significant Activity in Second Line RCC
Significant Activity in Second Line RCC Study CheckMate-025 Phase 3, nivolumab vs everlimous (1:1)1 METEOR study Phase 3, cabozanitnib vs everlimous (1:1)2 TIVO-1 Phase 3, subset crossing over to tivozanib following sorafenib progression3 Setting 2nd line RCC 2rd line RCC 2nd line RCC Size n=821 n=6
Slide 16: Potential Path to Value Creation: U.S. Registration Strategy in RCC
Potential Path to Value Creation U.S. Registration Strategy in RCC 2015 2016 ASCO 2015 Updated VEGF TKI refractory PFS data from TIVO-1 crossover FDA Feedback P3 refractory study for 3rd line and potential confirmatory study for first-line Phase 3 Registration Study in RCC Estimated 1Q 2016 Start 20
Slide 17: Tivozanib EU Registration Opportunity for 1st Line RCC
Tivozanib EU Registration Opportunity for 1st Line RCC
Slide 18: Opportunity for MAA Filing for RCC
Opportunity for MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study 301) R
Slide 19: Exclusive Licensing Agreement with EUSA
Exclusive Licensing Agreement with EUSA: Dec. 2015 Opportunity to realize value for tivozanib outside of North America Agreement Exclusive License Territory EU and other* Upfront (R&D) $2.5M Clinical and Regulatory Milestones** $37M R&D Reimbursement $22M Sales Milestones $335M Royalties Tiered roya
Slide 20: EUSA Pharma
EUSA Pharma Formed through acquisition from Jazz Pharmaceuticals (2015) Five approved specialty hospital products Several named-patient specialty hospital products Multi-national commercial infrastructure EUSA Pharma brand name Headquartered in the UK, with wholly-owned subs in the US, Germany, Fran
Slide 21: Exclusive Licensing Agreement with Pharmstandard
Exclusive Licensing Agreement with Pharmstandard in Russia, Ukraine and CIS: Aug. 2015 Agreement Exclusive license agreement Territory Russia, Ukraine and the Commonwealth of Independent States Upfront $1.5M* Marketing Authorization Milestone $7.5Mᶧ Additional Indication Milestones $3.0M Royalties H
Slide 22: Tivozanib Additional Development Opportunities
Tivozanib Additional Development Opportunities
Slide 23: Tivozanib Properties May Provide for Optimal Combination with PD1 Inhibitors
Tivozanib Properties May Provide for Optimal Combination with PD1 Inhibitors Where other VEGFR TKIs have had challenges combining with other agents, tivozanib has been demonstrated to safely combine at full dose in several studies: mRCC: Tivozanib + Temsirolimus (Torisel) mBC: Tivozanib + Paclitaxel
Slide 24: Low NRP-1 Biomarker Predictive for Tivozanib Benefit over Bevacizumab
Low NRP-1 Biomarker (50% of Pts) was Predictive for Tivozanib Benefit over Bevacizumab* Bevacizumab (n=28) Median PFS=11.2 mos Tivozanib (n=52) Median PFS=17.9 months NRP-1 lowa aUnstratified analysis: (n=80; events=31); log rank test P value=0.0075; HR (95% CI): 0.38 (0.183, 0.794). *Utilizing pred
Slide 25: Robust Pipeline Development Funded by Partnerships
Robust Pipeline Development Funded by Partnerships
Slide 26: Tivozanib: Non-Oncology Diseases of the Eye Agreement
Tivozanib: Non-Oncology Diseases of the Eye Agreement Research and Exclusive Option Agreement for Non-Oncology Diseases of the Eye Territory Worldwide ex-Asia Upfront $500,000 Option Term Milestones $2M at IND filing and $6M based upon the achievement of specified R&D, business goals Option Payment*
Slide 27: AV-380: Cachexia Agreement
AV-380: Cachexia Agreement Exclusive License Territory Worldwide Upfront* $15M Product Inventory Reimbursement (90-day option) $3.5M Clinical and Regulatory Milestones* $158M Sales Milestones $150M Royalties* Tiered royalties on product sales ranging from high single digits to a low double-digit Pro
Slide 28: Ficlatuzumab: Biomarker Selected 1st Line NSCLC
Ficlatuzumab: Biomarker Selected 1st Line NSCLC Agreement advances ficlatuzumab (HGF inhibitor MAb) with external funding while retaining significant downstream commercialization value Biodesix will fund up to $15 million of the cost of FOCAL and all companion diagnostic development costs 50/50 shar
Slide 29: AV-203: Superhumanized IgG1k MAb Inhibitor of ERBB3
AV-203: SuperhumanizedTM IgG1k MAb Inhibitor of ERBB3 Potent high affinity NRG-1/HRG binding inhibition Exclusively blocks ERBB3 signaling Potential for inducing ADCC Prevents NRG-1/HRG induced proliferation Opportunity to explore combinations with HER2 and EGFR Targeted Therapies Patent Term: 2031
Slide 30: Financials & Summary
Financials & Summary
Slide 31: Financial Highlights
Financial Highlights Estimated $34M in cash and securities as of year end 2015 Excludes $3.5M due from Novartis Sufficient to fund operations at least through the fourth quarter of 2017* >$40M in potential payments in next 18 months Ophthotech option exercise and development milestones Pharmstandard
Slide 32: Significant Progress During 2015
Significant Progress During 2015 Tivozanib Presentation of encouraging CRC data FDA feedback RCC registration plan ASCO presentation of refractory RCC data Rapporteur feedback for European filing Partnership in Russia (Pharmstandard) Partnership in EU (EUSA) Filing in Russia Pipeline AV-380 partners
Slide 33: Potential 2016/2017 Milestones
Potential 2016/2017 Milestones Tivozanib MAA filing (EUSA) Initiation of Phase 3 third-line confirmatory RCC study Initiation of Phase 1 PD-1 combination study Proof of concept in AMD (Ophthotech) Initiation of Phase 2/Phase 3 CRC study (with CDx identification) Regulatory decision in Russia/Ukraine
Slide 34: AVEO Oncology Highlights
AVEO Oncology Highlights Lead Asset: Tivozanib Core focus: retain North American tivozanib rights >$1Bn U.S. RCC market Partner Ex-N.A. (EUSA, Pharmstandard) and for ocular (Ophthotech) in 2014/15 Phase 3 TIVO-1 study demonstrated improved PFS in advanced RCC Study may support registration in Europe
Slide 35: January 2016 Corporate Overview
January 2016 Corporate Overview
AVEO Pharmaceuticals — Investor Presentation (January 2016) on 6ix